dihydroorotate dehydrogenase inhibitor

in Ph. I for RR-lymphoma

from opt. of literature molecule

Mol. Cancer Ther., Oct. 20, 2020

Agios Pharmaceuticals, Cambridge, MA

AG-636 (Agios Pharmaceuticals dihydroorotate dehydrogenase (DHODH) inhibitor clinical candidate)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks